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ABSTRACT
Background since 1994, over 50 families affected 
by the episodic ataxia type 1 disease spectrum have 
been described with mutations in KCNA1, encoding the 
voltage- gated K+ channel subunit Kv1.1. all of these 
mutations are either transmitted in an autosomal- 
dominant mode or found as de novo events.
Methods a patient presenting with a severe 
combination of dyskinesia and neonatal epileptic 
encephalopathy was sequenced by whole- exome 
sequencing (Wes). a candidate variant was tested using 
cellular assays and patch- clamp recordings.
Results Wes revealed a homozygous variant 
(p.Val368leu) in KCNA1, involving a conserved residue 
in the pore domain, close to the selectivity signature 
sequence for K+ ions (TVgYg). Functional analysis 
showed that mutant protein alone failed to produce 
functional channels in homozygous state, while 
coexpression with wild- type produced no effects on K+ 
currents, similar to wild- type protein alone. Treatment 
with oxcarbazepine, a sodium channel blocker, proved 
effective in controlling seizures.
Conclusion This newly identified variant is the first to 
be reported to act in a recessive mode of inheritance in 
KCNA1. These findings serve as a cautionary tale for the 
diagnosis of channelopathies, in which an unreported 
phenotypic presentation or mode of inheritance for 
the variant of interest can hinder the identification of 
causative variants and adequate treatment choice.
INTRoduCTIoN
Episodic ataxia 1 (OMIM: #160120) is a domi-
nantly inherited disease caused by missense variants 
in KCNA1, encoding the voltage- gated potassium 
channel subunit Kv1.1. The pathogenic causative 
variants may appear as de novo events or cosegre-
gate in several affected generations.1 The classical 
phenotype is defined by myokimia and periodic, 
intense ataxia episodes accompanied by spastic 
contractions.2 Patients with mutated KCNA1 
present with a wide range of clinical conditions, 
including epilepsy,3–5 neuromyotonia,6 migraine,7 
cerebellar dysfunction with cognitive delay,8 hypo-
magnesaemia,9 malignant hyperthermia,10 cata-
plexy,11 contractures12 or paroxysmal kinesigenic 
dyskinesia,13 among others. Thus, clinical heteroge-
neity is strong, even between patients carrying the 
same pathogenic variant.2
Kv1.1 is a member of the voltage- gated, Shaker- 
related subfamily of potassium channels. These 
channels regulate neuron excitability by contrib-
uting to the resting membrane potential and 
allowing repolarisation following an action poten-
tial. Kv channels are composed of four α subunits. 
Each subunit contains six transmembrane segments 
(S1–S6): the first four (S1–S4) comprise the 
voltage- sensor domain and S5, S6 and the S5–S6 
linker form the pore region. Therefore, a Kv pore 
is formed by S5–S6 domains belonging to four 
different subunits.14 Each pore domain contains the 
conserved sequence Thr- Val- Gly- Tyr- Gly (TVGYG), 
termed the ‘selectivity filter’, as it enables potas-
sium channels to be extremely selective for potas-
sium ions.15 Kv channels in the nervous system 
are mainly composed of Kv1.1, Kv1.2 and Kv1.4 
subunits, which coassemble into homotetrameric 
or heterotetrameric channels. Described KCNA1 
mutations result mostly in variable loss- of- function 
effects of the Kv1.1 channel, mainly classified into: 
(i) an impairment in protein expression, assembly 
or trafficking to the cell membrane or (ii) alter-
ations in channel function, such as reduced channel 
conductance, shifts in voltage- dependent activa-
tion or altered kinetics.2 16 17 Interestingly, given 
the heteromeric nature of potassium channels, 
mutated Kv1.1 subunits can alter the function of 
other subunits.2 As single mutations can exert an 
effect on various channel properties and because 
of genetic and environmental modifier factors, no 
strong genotype- phenotype associations have been 
established in these disorders.
In this study, we uncover a novel variant 
in KCNA1 segregating for the first time in an 
autosomal- recessive inheritance pattern, in a patient 
showing a severe, previously unreported, complex 
phenotype characterised by infantile- onset dyski-
nesia and neonatal onset developmental, epileptic 
encephalopathy. Functional testing indicated that 
this variant results in channel loss- of- function in the 
homozygous state only.
MATeRIAlS ANd MeThodS
Informed consent was obtained from all partici-
pants in this study according to the Declaration of 
Helsinki. The research project was approved by the 
Clinical Research Ethics Committee for Research 
Ethics Committee of the Bellvitge University 
Hospital (PR076/14).
Molecular studies
Genomic DNA was extracted from peripheral blood 
using standard methods. Whole- exome sequencing 
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(WES) was performed on patient DNA samples using the Sure-
Select XT Human All Exon V5 50 Mb kit (Agilent) for DNA 
capture and sequencing with the HiSeq 2000 Platform (Illu-
mina) at CNAG (Centre Nacional d’Anàlisi Genòmica, Barce-
lona). We prioritised non- synonymous coding variants that had a 
frequency lower than 0.01 in the ExAC, 1000 genomes and EVS 
databases. Missense variants were evaluated using several predic-
tors (PolyPhen2, SIFT, Mutation Taster, Meta- SVM). Candidate 
variants were validated and tested for cosegregation in all avail-
able family members by Sanger sequencing.
Sequence alignment was performed using ClustalOmega 
(https://www. ebi. ac. uk/ tools/ msa/clustalo/), with sequences 
extracted from NCBI. 3D models of KCNA1 wild- type or 
carrying the p.Val368Leu mutation were obtained using the 
SWISS- MODEL utility in the ExPASy webpage (https:// swiss-
model. expasy. org/, 5wie.1.B template). Structures were visual-
ised with PyMOL (https//www. pymol. org).
p.Val368Leu mutation was introduced into the p513- KCNA1 
vector, which contains the full- length wild- type KCNA1 cDNA,18 
using the QuikChange site- directed mutagenesis kit (Agilent 
Technologies). KCNA1 full- length cDNA (WT and p.Val368Leu) 
was amplified and cloned into the pEGFP- N3 vector (Clontech) 
using the InFusion HD Cloning Kit (Takara Bio), to generate 
two KCNA1- EGFP fusion vectors in which EGFP (Enhanced 
Green Fluorescent Protein) was fused downstream of KCNA1. 
All constructs were checked by Sanger sequencing.
For immunofluorescence analysis, HEK293T cells were seeded 
into 6- well plates to 90% confluence in 24 hours. Transfections 
were performed using 1 µg of vector (p513- KCNA1 or pKCNA1- 
EGFP, wild- type or mutated) and 5 µl Lipofectamine 2000 per 
well (Life Tech.). After transfection, cells were cultured for 48 
hours and then fixed in 4% paraformaldehyde. Cells transfected 
with p513- KCNA1 vectors were incubated overnight at 4°C with 
primary antibody anti- Kv1.1, clone K20/78 (1:50; NeuroMab) 
and for 1 hour at room temperature with secondary antibody 
Goat Anti- Mouse IgG Alexa Fluor 647 A-21236 (1/1000, Dako). 
DAPI was used to stain cell nuclei. Confocal microscopy images 
were acquired with a Leica TCS SL laser scanning confocal spec-
tral microscope using a 63× objective.
electrophysiological studies
HEK293T cells (100 000 cells) were transiently transfected using 
the Neon Transfection System (Life Technologies). The pCG- 
GFP plasmid (0.25 µg) was cotransfected with p513- KCNA1 
constructs (1.6 µg in p513- Kv1.1WT (wild- type) and p513- Kv1.1p.
Val368Leu or 0.8 µg of p513- Kv1.1WT +0.8 µg of p513- Kv1.1p.
Val368Leu to mimic a heterozygous condition). After transfection, 
cells were transferred to coverslip fragments coated with poly- 
L- lysine. Electrophysiological recordings were performed 24–48 
hours after transfection using the whole- cell configuration of 
the patch- clamp technique as adapted in our laboratory.19 Low- 
resistance electrodes (1.5–2.5 MΩ), capacity compensation and 
subtraction of linear leakage and capacity currents were used. 
Compensation of series resistance was <60% in all experiments. 
The holding potential was −80 mV. The bath solution was 
composed of 138 NaCl, 5.4 KCl, 1 CaCl2, 1.2 MgCl2, 10 glucose 
and 10 HEPES (in mM), pH 7.4; for the solution in the pipette 
and inside the cell, 100 K- glutamate, 20 K- fluoride, 20 KCl, 1 
Na2- ATP and 10 HEPES, pH 7.2. In the 70 K external solution, 
70 mM NaCl was replaced with 70 mM KCl. All experiments 
were conducted at room temperature (20°C–25°C). Voltage- 
clamp recordings were obtained with an EPC-10 patch- clamp 
amplifier using standard protocols designed with Pulse software 
(Heka Elektronik). Data were filtered at 10 kHz, digitalised at a 
sampling interval of 20 μs and stored on a Macintosh computer. 
Off- line analysis of data was performed using Pulse Fit (Heka 
Elektronik). Current densities were obtained by normalising the 
current amplitude to the cell membrane capacitance. To obtain 
the conductance versus voltage curves, the amplitude of the tail 
currents, recorded in the presence of the 70 K external solu-
tion, was normalised to the maximum current and plotted as a 
function of the pulse potential. The curves reflect the best fits to 
the averaged current- voltage data points, according to the Boltz-
mann equation: I=Imax/(1 + exp((V – V1⁄2)/k)), where I is the 
current measured at each test potential (V); Imax is the maximal 
current; V1⁄2 is the half- maximal activation voltage; k is the slope 
factor.
Statistical analysis
Data are expressed as the mean±SEM. Statistically significant 
differences were evaluated with Student’s t- test, with a threshold 
set at p<0.05.
ReSulTS
Index patient II-1 (figure 1A), a 6- year- old girl, third daughter of 
healthy, consanguineous parents of Moroccan origin, presented 
with seizures on the 19th day of life, consisting of tonic posture 
with impaired consciousness, desaturation and cyanosis. She 
was treated with phenobarbital with partial control. Meta-
bolic screening (blood, urine and cerebrospinal fluid), karyo-
type, brain MRI, electromyography and a nerve conduction 
velocity test yielded normal results. Online supplementary 
video- electroencephalography showed a slow and disorgan-
ised background with occipital paroxysmal activity. She devel-
oped weekly tonic- clonic seizures with impaired consciousness, 
usually triggered by febrile episodes or infections, and refractory 
to phenobarbital and valproic acid. Very good seizure control 
was observed after introduction of the sodium channel blocker 
oxcarbazepine. At 3 years old, she presented generalised choreo- 
dystonic movements associated with facial grimacing that wors-
ened with stress and anger. At the last follow- up in March 2019, 
she showed impairment of gross motor skills, walking with 
support or use of a wheelchair, although she could sit normally 
(Gross Motor Function Classification System (GMFCS) grade 
III). She handled objects with difficulty (Manual Ability Classifi-
cation System (MACS) grade III). She also exhibited severe intel-
lectual disability with a lack of communication and expressive 
language and behavioural problems.
Singleton WES analysis in patient II-1 revealed 12 homozy-
gous extremely rare variants in regions of loss of heterozygosity, 
compatible with this family consanguineous nature. Among these 
variants, a missense variant in the KCNA1 gene, p.Val368Leu 
(Chr12:5 021 646G>C GRCh37, NM_000217:c.1102G>C) 
was considered a plausible candidate given the phenotypic 
presentation of the patient. No other candidate rare variants 
compatible with other modes of inheritance or variants in genes 
that would remotely relate to the phenotypic features were 
detected. This variant is completely absent from control data-
bases (1000 Genomes, ExAC, gnomAD). Although KCNA1 has 
only been associated with dominant conditions (mainly with 
episodic ataxia/myokymia syndrome, OMIM #160120) in more 
than 50 families and 260 patients described so far, this variant 
cosegregated in a recessive mode of inheritance, as all other 
family members were heterozygous healthy carriers, without 
a family history of ataxia, dystonia, myokimia or migraine 
(figure 1A). Although some mutations have been identified in the 
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Figure 1 Family tree and KCNA1 p.Val368leu variant features. (a) Family tree. square: male, circle: female. solid black symbols: affected individual. White 
symbols: unaffected carriers. (B) a representation of Kv1.1 protein in the cell membrane, showing all mutations identified up to 2019 (updated and adapted 
from2). The position of the p.Val368leu mutation in the pore region is indicated in bold. (c) amino acid sequence alignment of Kv1.1 subunits across several 
species and other members of the human Kv1 family demonstrates conservation of the Val368 residue. Blue indicates the pore intramembrane portion and 
red indicates the conserved sequence motif functioning as a selectivity filter (TVgYg). (D) structural models of wild- type and p.Val368leu KCNA1 sequences. 
TVgYg, Thr- Val- gly- Tyr- gly.
pore region, this is the first variant reported in the S5- S6 linker 
(figure 1B). This residue is well conserved throughout evolution 
(figure 1C), and in silico tools predict the amino acid change 
to be deleterious. Alignment of human Kv1 channels also indi-
cates that the Val368 residue is conserved among all members 
of this protein family. Homology models predict this amino 
acid to directly interact with the conserved signature sequence, 
TVGYG, which functions as a selectivity filter to conduct K+ ions 
(figure 1D).14 15 20 Applying ACMG/AMP (American College of 
Medical Genetics/ Association for Medical Pathology) guidelines 
for variant interpretation,21 we attributed a variant of unknown 
significance status to this amino acid change.
Intrigued by a potential novel inheritance mode, a distinct 
phenotype for a KCNA1- related disorder, we cloned wild- 
type and mutant cDNA sequences into expression vectors 
to assay for localisation. On transfection in HEK293T cells, 
p.Val368Leu mutant protein localised to the cell membrane 
in a way similar to the wild- type protein, both using anti- 
Kv1.1 immunofluorescence or KCNA1- EGFP fusion vectors, 
implying the lack of trafficking or expression defects conferred 
by the variant (figure 2A and B). To test the effects of the 
p.Val368Leu variant on Kv1.1 channel function, we expressed 
the wild- type protein, the mutant, and a combination of both 
in HEK293T cells. Cells expressing wild- type Kv1.1 (n=14) 
showed voltage- dependent potassium currents with a peak 
current density of 150±24 pA/pF at +40 mV (figure 2C and 
D). To mimic the heterozygous condition, we injected equiv-
alent amounts of wild- type and Kv1.1p.Val368Leu cDNAs and 
found currents almost identical to those of wild- type Kv1.1 
(peak current density of 143±23 pA/pF at +40 mV, n=15). 
In contrast, expression of Kv1.1p.Val368Leu yielded significantly 
smaller currents (peak current density of 35±4 pA/pF at +40 
mV, n=15) indistinguishable from the negative control (mock 
transfected, not shown) or endogenous HEK293T potassium 
currents. Thus, we conclude that the Kv1.1p.Val368Leu mutant 
does not produce functional channels. To test whether the 
coexpression of the p.Val368Leu subunit could affect the 
voltage dependence of the wild- type Kv1.1, we analysed the 
conductance vs voltage relationship of the wild- type and 
heteromeric wild- type/p.Val368Leu channels. No statistically 
significant differences were observed in the voltage depen-
dence of activation (figure 2E and online supplementary table 
1) or in the activation/inactivation kinetics (data not shown) 
between wild- type and heteromeric Kv1.1 channels.
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Figure 2 Functional testing of KCNA1 p.Val368leu recessive mutation. (a) immunofluorescence of heK293T cells transfected with p513- Kcna1WT and 
p513- Kcna1p.Val368leu. Blue: DaPi. green: pegFP. red: Kcna1 (anti- Kv1.1 antibody). (B) immunofluorescence of heK293T cells transfected with Kcna1WT- 
egFP and Kcna1p.Val368leu- egFP. Blue: DaPi. green: Kcna1- egFP. (c–e) electrophysiological analysis in cells transfected with p513- Kcna1WT (WT, 1.6 
µg), p513- Kcna1p.Val368leu (p.Val368leu, 1.6 µg) or both (WT/p.Val368leu, 0.8 µg+0.8 µg). (c) representative traces of Kv1.1 outward currents evoked in 
heK293T cells transiently expressing WT, WT/p.Val368leu or p.Val368leu channels. currents were recorded at various membrane potentials applied for 50 
ms, from −60 to +40 mV in 10 mV increments, from a holding potential of −80 mV. For clarity, only currents registered at –40, –20, 0, +20 and +40 mV 
are shown. (D) averaged current density- voltage curves for WT, WT/p.Val368leu or p.Val368leu channels. (e) conductance versus voltage relationships for 
the WT and WT/p.Val368leu channels. The lines reflect the best fits to the averaged current- voltage data points, according to the Boltzmann equation as 
described in the Methods. Values are expressed as the mean±seM.
dISCuSSIoN
We report a child affected by a severe neurological disease 
in which WES uncovers a novel mode of inheritance for a 
KCNA1- associated disorder. Our patient also shows a previ-
ously unreported combination of developmental and epileptic 
encephalopathy and dyskinesia of neonatal onset, a novel clin-
ical presentation and much more severe phenotype than the clas-
sical episodic ataxia and myokimia syndromes most frequently 
associated with this gene.2 Indeed, infantile- onset epileptic 
encephalopathy with cognitive impairment has been reported 
in only four patients harbouring heterozygous de novo KCNA1 
variants within the Kv- specific PVP motif, which is essential for 
channel gating.5 22 A similar phenotype has also been described 
in KCNA2- mutated patients.23
Functional studies of the p.Val368Leu mutation revealed that 
the mutant channel is expressed and reaches the cell membrane 
but causes a strong loss- of- function effect. The p.Val368Leu 
substitution affects a residue that is well conserved through evolu-
tion, located behind the selectivity filter of Kv1.1. It has been 
suggested that Val368 makes hydrophobic contact with Tyr375 
residue’s side chain located in the signature sequence (TVGYG) 
of the selectivity filter, playing an important role in maintaining 
its structural integrity.20 Consequently, the substitution of Val by 
Leu (whose side chain is more voluminous) could seriously affect 
the interaction with Tyr375, destabilising the selectivity filter 
and preventing K+ efflux through the pore. Indeed, this amino 
acid position is crucial for efficient channel gating, as a mutation 
in the equivalent amino acid of the prokaryotic channel KcsA 
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(Glu71Ala) was shown to abrogate this channel’s natural inac-
tivation process.24 In addition, the p.Val438Ala mutation in the 
pore region of the Shaker channel (analogous to p.Glu71Ala in 
KcsA) also resulted into altered C- type inactivation, in contrast 
to several other mutations generated in this channel.25 Another 
previously published mutation in the vicinity of the selectivity 
filter also results in the abolishment of ionic currents in the 
homologous Shaker potassium channel, in line with our results 
for p.Val368Leu.26 Thus, our results support a severe alter-
ation of the structural integrity of the channel and block in ion 
conduction caused by the substitution of the Val368 residue in 
the Kv family.
Patch- clamp studies of the p.Val368Leu mutation indicate 
that the electrophysiological properties of the heterozygous 
state are not significantly different from the wild- type condition. 
Although we cannot fully exclude a dominant negative effect, 
these results are consistent with a recessive effect of the mutant 
allele leading to the absence of clinical manifestations in hetero-
zygote carriers and are analogous to electrophysiological results 
obtained for mutations in KCNA223 and recessive mutations in 
KCNQ1,27–29 in which cotransfection of wild- type and mutated 
cDNA also lead to currents hardly different from the wild- type- 
alone condition. Contrary to KCNA1 mutations behaving in 
a dominant negative way, the presence of one wild- type allele 
efficiently counters the loss- of- function effect of the mutated 
p.Val368Leu allele and prevents heterozygous carriers from 
developing the disease (figure 2). We posit that transfection of 
p.Val368Leu- mutant cDNA alone produces channels containing 
solely mutant KCNA1 subunits, which do not allow K+ currents, 
while cotransfection of wild- type and mutant cDNAs generates 
channels containing some wild- type subunits for the most part. In 
a mixed channel situation, the p.Val368Leu- mutant subunits do 
not significantly interfere with the wild- type subunits, who carry 
out their function normally, producing currents in the range of 
wild- type tetramers. While KCNA1 and KCNA2 mutations can 
give rise to similar epilepsy phenotypes and both have been asso-
ciated with an autosomal dominant mode, pLI and pRec scores 
(which measure probability of intolerance to loss- of- function 
variants in the heterozygous and recessive state, respectively),30 
predict that loss- of- function mutations in KCNA1 (pLI: 0.0959; 
pRec: 0.897) should behave in a recessive way, while in KCNA2 
(pLI: 0.871; pRec: 0.129), this probability is reduced. Concor-
dantly, most KCNA1 mutations are missense variants exerting 
a dominant negative effect which partially abolishes activity of 
the wild type protein, in contrast to our variant, which does not 
affect wild- type function2 18 and behaves as a loss of function 
allele. It is worth noting that some dominant negative muta-
tions in KCNA1 have been associated with epilepsy,3 although 
less severely than in our case. This is reinforced by the observa-
tion that Kcna1 knockout mice only show spontaneous seizures 
in the homozygous state.31 Interestingly, our patient exhibited 
seizure control with a sodium channel blocker (oxcarbazepine). 
Carbazepine compounds are widely used anticonvulsants that 
lead to the stabilisation of hyper- excited neural membranes, 
with well- documented effects in a rat model of myokimia, 
neuromyotonia and epilepsy harbouring a missense mutation in 
Kcna1 (Kv1.1S309T).32 The antiepileptic effect of oxcarbazepine 
was also reported in one patient harbouring a dominant negative 
variant in KCNA1.12 Interestingly, anticonvulsant effects of these 
compounds may also be attributed to enhanced conductance of 
potassium channels.33 Thus, this case adds to the bulk of litera-
ture showing improved disease management driven by precision 
diagnosis and underlines the pertinence of exome sequencing as 
a first- tier test for early- onset epileptic encephalopathies.34 35
In summary, we have uncovered a novel phenotype and mode 
of inheritance related to a pathogenic loss- of- function variants in 
the KCNA1 gene. The location of this mutation close to the selec-
tivity filter demands some caution in interpreting variants, also 
for other channelopathies, for which the clinical presentation 
or mode of inheritance may not be concordant with previous 
descriptions.
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